We are thrilled to announce that QurCan Therapeutics has been selected as an awardee of the Ontario Genomics accelerator program #BioCreate, which provides funding and business support to highly-vetted biotechnology companies creating game-changing genomic technologies. The award supports the advancement of QurCan’s genomic medicine program, focused on developing the company’s proprietary nanoparticle platform technology to boost the effectiveness of cancer-fighting RNA therapeutics to improve the quality of life for patients. We would like to express our gratitude to Ontario Genomics and the BioCreate team for their support of our innovative technology. #Ontariogenomics #rnatherapeutics #geneediting
QurCan Therapeutics Inc.
Pharmaceutical Manufacturing
Toronto, ON 686 followers
Advanced Delivery Technology To Unlock The Full Potential of Biological Therapeutics
About us
QurCan Therapeutics (formerly Nanology Labs Inc) is a biotechnology company using advanced nanoparticle drug-delivery technology to unleash the immense potential of next-generation biological and genetic medicine and deliver life-changing therapeutics. QurCan's next generation nanoparticle platform, TERP, enables tissue-selective delivery of nucleotides and biological therapeutics to extra-hepatic sites, including brain and spleen. TERP technology is a breakthrough technology with the great potential to deliver a new era of disease-modifying genetic medicine that will make a difference to patients with a wide range of unmet medical needs.
- Website
-
http://www.qurcan.com
External link for QurCan Therapeutics Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1 employee
- Headquarters
- Toronto, ON
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Gene Delivery, CNS delivery, Tissue targeting, and nanoparticle technology
Locations
-
Primary
Get directions
661 Univeresity Ave.
Toronto, ON M5G1M1, CA
Employees at QurCan Therapeutics Inc.
Updates
-
We are delighted to announce that QurCan has been selected to participate in Novo Nordisk's Co-Creation Greenhouse Program. Anchored through the Novo Nordisk #BioInnovationHub, this collaboration provides QurCan with funding and deep scientific and technical expertise in translational and drug development. The collaboration supports a proof-of-concept study that explores QurCan's proprietary TERP nanoparticle technology for the selective tissue delivery of nucleotides. #genetherapy #novonordisk #nanoparticles #rna #therapeutics
-
-
We are thrilled to announce that QurCan has been selected as an awardee of the Advancing Oncology InnoVAtion QuickFire Challenge by Johnson & Johnson Innovation. The award aims to support the advancement of QurCan’s genetic medicine program, focused on developing a novel in-vivo immune cell therapy. This program utilizes the company’s proprietary nanoparticle technology to selectively deliver mRNAs to the spleen and specific immune cells, offering an innovative precision medicine strategy for cancer treatment. We would like to express our gratitude to Johnson & Johnson Innovation, Carilion Clinic Innovation, Verge Alliance, and the Virginia Tech Corporate Research Center (VTCRC) for their support of our innovative technology. #nanoparticles #genetherapy #cartcelltherapy #mrna #johnsonandjohnson #CarilionClinic #VTCRC
-